Medicare Enrolled
Dr. Mathew Meeneghan, M.D.
Internal Medicine · Bastrop, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Meeneghan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Meeneghan? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Meeneghan
Dr. Mathew Meeneghan is an internal medicine in Bastrop, TX, with 17 years in practice. Based on federal Medicare data, Dr. Meeneghan performed 92,827 Medicare services across 4,751 unique beneficiaries.
Between the years covered by Open Payments, Dr. Meeneghan received a total of $4,409 from 40 pharmaceutical and/or device companies across 191 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Meeneghan is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice▲ Top 0% volume in TX$ $4,409 industry payments
Medicare Practice Summary
Medicare Utilization ↗92,827
Medicare services
Top 0% in TX for internal medicine
4,751
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,460 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 34,170 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 12,400 | $43 | $137 |
| Iron sucrose injection (Venofer) | 10,700 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) | 6,750 | $0 | $5 |
| Darbepoetin injection (Aranesp) for anemia | 5,330 | $2 | $20 |
| Denosumab injection (Prolia/Xgeva) | 2,400 | $18 | $66 |
| Dexamethasone injection (steroid) | 2,173 | $0 | $1 |
| Immune globulin infusion (Octagam) | 2,150 | $34 | $235 |
| Injection, bortezomib, 0.1 mg | 1,750 | $4 | $116 |
| Complete blood count (CBC) with differential | 1,709 | $8 | $36 |
| Blood draw (venipuncture) | 1,639 | $8 | $20 |
| Comprehensive metabolic blood panel | 1,476 | $10 | $64 |
| Anti-nausea injection (Aloxi/palonosetron) | 760 | $1 | $114 |
| Immunoglobulin level test | 637 | $9 | $56 |
| Injection, fluorouracil, 500 mg | 625 | $2 | $13 |
| Injection, granisetron hydrochloride, 100 mcg | 500 | $0 | $24 |
| Office visit, established patient (30-39 min) | 445 | $91 | $368 |
| Measurement of immunoglobulin light chains | 396 | $17 | $60 |
| Administration of chemotherapy into vein, 1 hour or less | 373 | $101 | $707 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 372 | $78 | $1,348 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 330 | $22 | $157 |
| Injection of additional new drug or substance into vein | 326 | $12 | $108 |
| Lactate dehydrogenase (enzyme) level | 319 | $6 | $31 |
| Office visit, established patient (20-29 min) | 279 | $62 | $250 |
| Ferritin level test (iron stores) | 231 | $13 | $60 |
| Iron level test | 231 | $6 | $27 |
| Iron binding capacity test | 231 | $8 | $35 |
| Injection, zoledronic acid, 1 mg | 215 | $7 | $431 |
| Office visit, established patient, complex (40-54 min) | 206 | $131 | $496 |
| Drug injection, under skin or into muscle | 195 | $11 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 179 | $49 | $313 |
| Infusion, normal saline solution , 1000 cc | 179 | $2 | $19 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 163 | $55 | $211 |
| Carcinoembryonic antigen (cea) protein level | 160 | $19 | $99 |
| Injection, carboplatin, 50 mg | 156 | $2 | $300 |
| Complete blood count (CBC), automated | 138 | $6 | $34 |
| Microscopic examination for white blood cells with manual cell count | 137 | $4 | $22 |
| Magnesium level test | 135 | $7 | $29 |
| Reticulated (young) platelet measurement | 124 | $35 | $143 |
| Administration of chemotherapy into vein, each additional hour | 124 | $22 | $161 |
| Protein measurement, serum | 112 | $11 | $99 |
| Immunologic analysis technique on serum | 112 | $29 | $108 |
| Immunologic analysis technique on serum (immunofixation) | 112 | $22 | $160 |
| Injection, magnesium sulfate, per 500 mg | 96 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 95 | $16 | $100 |
| Hospital follow-up visit, moderate complexity | 94 | $62 | $247 |
| Infusion into a vein for hydration, 31-60 minutes | 87 | $26 | $256 |
| Injection, diphenhydramine hcl, up to 50 mg | 82 | $1 | $7 |
| Infusion into a vein for hydration, each additional hour | 75 | $10 | $75 |
| New patient office visit (45-59 min) | 73 | $114 | $565 |
| Administration of additional new drug or substance into vein, 1 hour or less | 72 | $50 | $344 |
| PSA test (prostate cancer screening) | 68 | $18 | $94 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 65 | $336 | $1,722 |
| Administration of additional new drug or substance into vein using push technique | 61 | $42 | $289 |
| Vitamin D level test | 60 | $29 | $250 |
| Initial hospital admission, high complexity | 58 | $133 | $694 |
| Hospital follow-up visit, high complexity | 56 | $92 | $357 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 54 | $125 | $500 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 50 | $26 | $145 |
| Injection of drug or substance into vein | 49 | $30 | $247 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 47 | $133 | $3,675 |
| Unclassified drugs | 46 | $1 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 45 | $15 | $94 |
| New patient office visit, complex (60-74 min) | 44 | $160 | $709 |
| Vitamin B-12 level test | 33 | $15 | $76 |
| Folic acid level test | 33 | $14 | $73 |
| Application of on-body injector for under skin injection | 31 | $14 | $96 |
| Irrigation of implanted venous access drug delivery device | 31 | $19 | $114 |
| Thyroid stimulating hormone (TSH) test | 28 | $16 | $80 |
| Injection, hydromorphone, up to 4 mg | 26 | $3 | $9 |
| Red blood count, automated test | 25 | $4 | $23 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 25 | $91 | $657 |
| Drawing of blood for a medical problem | 20 | $58 | $264 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 19 | $1,225 | $4,802 |
| Urinalysis with microscopic exam | 18 | $3 | $28 |
| Basic metabolic blood panel | 12 | $8 | $49 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
40.3% high complexity
49.3% medium
10.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,409
Total received (2019-2024)
Avg $735/year across 6 years
Top 18% in TX for internal medicine
40
Companies
191
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,187 (95.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$222 (5.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,181
2023$2,005
2022$767
2021$12
2020$163
2019$281
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$645
Novartis Pharmaceuticals Corporation
$445
AstraZeneca Pharmaceuticals LP
$366
Seagen Inc.
$271
Merck Sharp & Dohme LLC
$256
Genentech USA, Inc.
$237
PFIZER INC.
$221
Alexion Pharmaceuticals, Inc.
$175
Incyte Corporation
$149
JAZZ PHARMACEUTICALS INC.
$122
Eisai Inc.
$115
Gilead Sciences, Inc.
$115
E.R. Squibb & Sons, L.L.C.
$111
Lilly USA, LLC
$92
Puma Biotechnology, Inc.
$91
Adaptive Biotechnologies Corporation
$88
ABBVIE INC.
$83
GlaxoSmithKline, LLC.
$65
ARRAY BIOPHARMA INC
$64
Takeda Pharmaceuticals U.S.A., Inc.
$59
MorphoSys, US Inc.
$59
Amgen Inc.
$59
Kite Pharma, Inc.
$58
Apellis Pharmaceuticals, Inc.
$55
Karyopharm Therapeutics Inc.
$49
TAIHO ONCOLOGY, INC.
$46
Celgene Corporation
$36
ADC Therapeutics America, Inc.
$36
Stemline Therapeutics Inc.
$34
Tempus AI, Inc
$23
Sobi, Inc
$22
SOBI, INC
$21
AVEO Pharmaceuticals, Inc.
$20
EMD Serono, Inc.
$20
Agios Pharmaceuticals, Inc.
$19
Ipsen Biopharmaceuticals, Inc
$19
Rigel Pharmaceuticals, Inc.
$19
Regeneron Healthcare Solutions, Inc.
$17
SERVIER PHARMACEUTICALS LLC
$15
TerSera Therapeutics LLC
$13
Top 3 companies account for 33.0% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ADVATE · BLENREP · BOSULIF · BRAFTOVI · CALQUENCE · DARZALEX · DOPTELET · ENHERTU · ERLEADA · Empaveli · FOTIVDA · FRUZAQLA · Fabhalta · Gazyva · IBRANCE · IMFINZI · INLYTA · JAKAFI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · MONJUVI · NERLYNX · NINLARO · OJJAARA · OXBRYTA · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PROMACTA · PYRUKYND · Perjeta · Pomalyst · REBLOZYL · RYBREVANT · Rezlidhia · Rituxan · SCEMBLIX · TECVAYLI · TUKYSA · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VONJO · VYXEOS · Venclexta · XALKORI · XPOVIO · XTANDI · Yescarta · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (95%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $5 per 100 Medicare services performed
Geographic Context
Internal Medicines within 10 mi
50
Per 100K population
48.8
County median income
$82,730
Nearest hospital
ASCENSION SETON SMITHVILLE
12.0 mi
12.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Meeneghan is a mixed practice specialist, with above-average Medicare volume (top 0% in TX), and high industry engagement (low-engagement, top 18%), with 17 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Meeneghan experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Meeneghan performed 34,170 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Meeneghan receive payments from pharmaceutical companies?
Yes. Dr. Meeneghan received a total of $4,409 from 40 companies across 191 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Meeneghan's costs compare to other internal medicines in Bastrop?
Dr. Meeneghan's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Meeneghan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicines in Bastrop
Browse internal medicines in Bastrop ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicines in TX
Internal Medicines ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicines in TX
Which TX internal medicines receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology